Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Br J Psychiatry. 2018 Oct 25;213(6):704–708. doi: 10.1192/bjp.2018.211

Figure 3. Pre-treatment PTSD severity and expectancy predicting early response by treatment condition.

Figure 3.

Higher pre-treatment PTSD severity predicted early response in PE but not sertraline. Higher expectancy predicted early response in sertraline but not PE. Values represent estimated likelihood of early response for patients with low (25th percentile), medium (50th percentile) and high (75th percentile) pre-treatment PTSD severity or expectancy, separated by treatment type. PSS-I = PTSD Symptom Scale – Interview. For pre-treatment PTSD severity, in prolonged exposure, B = −1.11, p < .001, 95% CI [−1.72, −0.49] and in sertraline, B = −0.31, p (ns), 95% CI [−0.88, 0.26]. For expectancy of therapeutic outcome, in prolonged exposure, B = 0.26, p (ns), 95% CI [−0.29, 0.81] and in sertraline, B = 1.35, p = .01, 95% CI [0.35, 2.36].